Atypical antipsychotic drug use and diabetes

Psychotherapy and Psychosomatics

Volumn 71, Issue 5, 2002, Pages 244-254

  Ananth, Jambur ^a   Venkatesh, Ravi ^a   Burgoyne, Karl ^a   Gunatilake, Sarath ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b Metropolitan State Hospital   (United States)

Author keywords

Atypical antipsychotic drug induced diabetes, management; Atypical antipsychotic drug related diabetes, mechanism; Atypical antipsychotic drugs; Diabetes; Hyperglycemia

Indexed keywords

ACARBOSE; CLOZAPINE; DOPAMINE 2 RECEPTOR; GLIMEPIRIDE; GLIPIZIDE; INSULIN; LEPTIN; METFORMIN; OLANZAPINE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; QUETIAPINE; REPAGLINIDE; RISPERIDONE; ROSIGLITAZONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TRIACYLGLYCEROL; ZIPRASIDONE;

ARTICLE; DIABETIC KETOACIDOSIS; DISEASE PREDISPOSITION; DOPAMINE RECEPTOR BLOCKING; DRUG USE; ETHNOLOGY; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCHIZOPHRENIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; OBESITY; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 0036041538     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064807     Document Type: Article

References (95)

1. Glucose tolerance in schizophrenia
2. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients
3. Diabetes and schizophrenia - A preliminary study
4. Glucose-insulin metabolism in chronic schizophrenia
5. Diabetes mellitus in schizophrenic patients
6. Psychotropic drugs, diabetes and chronic mental patient
7. Blood sugar levels in patients treated with chloropromazine
8. Effect of clozapine-quetiapine combination therapy on weight gain and glycemic control
9. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
10. Diabetic ketoacidosis as a side effect of clozapine: A case report
11. Clozapine and associated diabetes mellitus
12. Diabetic ketoacidosis associated with clozapine treatment
13. Clozapine monotherapy and ketoacidosis
14. Diabetes mellitus after treatment with clozapine
15. Neuroleptic malignant syndrome and hyperosmolar, non-ketotic hyperglycaemic coma
16. Diabetic ketoacidosis and clozapine
17. Diabetic ketoacidosis with clozapine treatment
18. Clozapine-induced diabetes ketoacidosis
19. Diabetes mellitus associated with clozapine therapy
20. Hyperglycemia, hyperlipemia and periodic paralysis: A case report of new side effects of clozapine
21. Diabetes as a result of atypical anti-psychotic drugs - A report of three cases
22. Severe hyperglycemia associated with high doses of clozapine
23. Schizophrenia and diabetes mellitus
24. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment
25. Ketoacidosis as a side-effect of clozapine: A case report
26. Lactic acidosis and fatal myocardial failure due to clozapine
27. Diabetic ketoacidosis from clozapine and lithium cotreatment
28. Insulin-resistant hyperglycemia induced by clozapine
29. Novel antipsychotics and new onset diabetes
30. Lethal interaction of clozapine and buspirone?
31. Pregnancy of a patient treated with clozapine
32. Reassessment of the side effect profile of clozapine
33. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
34. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
35. Diabetic ketoacidosis with olanzapine treatment
36. Hyperglycemia associated with olanzapine
37. Olanzapine-induced ketoacidosis with diabetes mellitus
38. Hyperglycemia and olanzapine
39. Olanzapine-induced glucose dysregulation
40. Olanzapine induced glucose intolerance in African American patients
41. Hyperglycemia and ketoacidosis associated with olanzapine
42. Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
43. Weight gain and glucose metabolism with atypical antipsychotics
44. Diabetic ketoacidosis associated with risperidone treatment?
45. New-onset diabetes associated with the initiation of quetiapine treatment
46. New onset of diabetes mellitus associated with quetiapine
47. Weight gain: Side effect of atypical neuroleptics?
48. Chlorpromazine-induced diabetes
49. Phenothiazines and diabetes in hospitalized women
50. Effects of quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women
51. Hyperglycemic properties of serotonin receptor antagonists
52. Effects of the 5-HT1C/5-5HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat
53. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: Influence on muscle glycogen synthase and insulin receptor kinase activity
54. Radioreceptor binding profile of the atypical antipsychotic olanzapine
55. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report
56. Positional cloning of the mouse obese gene and its human homologue
57. Food intake and energy balance
58. Regulation of circulating leptins in humans
59. Leptin enhances glycogen storage in hepatocytes by inhibition of phosphorylase and exerts an additive effect with insulin
60. Gender differences in serum leptin levels in humans
61. Leptin concentrations and insulin sensitivity in normoglycemic men
62. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
63. Direct stimulation of basal insulin secretion by physiological concentration of leptin in pancreatic beta cells
64. Serum leptin levels increase rapidly after initiation of clozapine therapy
65. Physiological secretion of growth hormone secretion
66. Insulin-like growth factor (IGF) binding proteins: The role of the serum IGFBPs in regulation of IGF availability
67. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
68. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
69. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q
70. Mutation in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY 3)
71. Familial hyperproinsulinemia due to a proposed defect in conversion of proinsulin to insulin
72. Familial hyperproinsulinemia - Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion
73. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus
74. Nonsense mutation in the glucokinase gene causes early-onset non-insulin dependent diabetes mellitus
75. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system
76. Syndrome X: 6 Years later
77. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions
78. The effect of clozapine on glucose metabolism
79. Are psychoactive drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?
80. Serum triglycerides in patients treated with clozapine
81. Olanzapine increases weight and serum triglyceride levels
82. Elevated serum triglycerides on clozapine resolve with risperidone
83. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine
84. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients
85. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin
86. Chlorpromazine and related phenothiazines inhibit the ATP sensitive K+ channel
87. Prevalence and correlates of diabetes in national schizophrenia samples
88. Ciglitazone, a new hypoglycemic agent. 1. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal streptozotocin-diabetic rats
89. Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents
90. Actions of novel antidiabetic agent englitazone in hyperglycemic, hyperinsulinemic ob/ob mice
91. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat
92. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects
93. Thiazolidinediones